Project Grant R43CA298783
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Cancure LLC (XMSVDPZ8ELY1)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $404,994 Project Grant (CFDA 93.396 - Cancer Biology Research) to Aperture Bio, Inc., a woman-owned small business in Cambridge, MA. The objective of this 1-year grant, with a start date of March 1, 2025, is to determine the feasibility of using Aperture Bio's platform for preclinical drug development applications in organoids, as well as process development and research applications in cell...
This $353,204 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports the development of a novel technology called Cell-MAPP by Pumpkinseed Technologies Inc., a for-profit company located in Palo Alto, California. The goal of this Phase I Small Business Innovation Research (SBIR) project is to demonstrate and advance Cell-MAPP, a live-cell monitoring system that enables continuous, high-throughput analysis of T cell states...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,388 to Histone Therapeutics, a woman-owned small business, aims to epigenetically modify natural killer (NK) cells to enhance their ability to detect and kill cancer cells. The goal is to develop a broad-spectrum NK cell therapy that can be used in combination with current cancer treatments to improve effectiveness without increasing side effects. The project will assess...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Promilead, LLC to evaluate a small-molecule compound, USCYL01, as a potential therapy to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) assess the toxicity and pharmacokinetic properties of USCYL01 in vitro and in vivo, and 2) test USCYL01 as an adjunct to ICI plus...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...